预约演示
更新于：2026-09-08
Aripiprazole
阿立哌唑
更新于：2026-09-08
概要
基本信息
简介阿立哌唑，商品名 Abilify Discmelt®，是一种非典型抗精神病药物，用于治疗多种情绪和精神病，包括但不限于精神分裂症、I 型双相情感障碍、重度抑郁症、易激惹相关疾病、自闭症和图雷特综合症。作用机制为5-HT2A 激动剂和 D2 受体激动剂。阿立哌唑于2002 年首次获得美国 FDA 批准，由大冢控股开发。它的主要适应症是用于治疗精神分裂症。 |
药物类型 小分子化药 |
别名 ABILIFY MAINTENA、Abilify MyCite、Abilify Prolonged Release Aqueous Suspension + [36] |
作用方式 激动剂、拮抗剂 |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor激动剂(多巴胺D2受体激动剂) |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-11-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H27Cl2N3O2 |
InChIKeyCEUORZQYGODEFX-UHFFFAOYSA-N |
CAS号129722-12-9 |
关联
539
项与 阿立哌唑 相关的临床试验NCT07714213
Prospective, Randomized, Double-blind, Placebo-controlled Phase 2a Trial of Low-dose Aripiprazole in Patients With Neuropsychiatric Impairment in Post-acute Infectious Syndrome (PAIS) Including Post-COVID-19 Condition (PCC)
CTRI/2026/07/113210
A pilot study on the efficacy of aripiprazole in children and adolescents with Oppositional defiant disorder - nil
NCT05545891
A Double-Blind, Placebo Controlled Study of Aripiprazole in Body Focused Repetitive Behaviors
100 项与 阿立哌唑 相关的临床结果
登录后查看更多信息
100 项与 阿立哌唑 相关的转化医学
登录后查看更多信息
100 项与 阿立哌唑 相关的专利（医药）
登录后查看更多信息
6,390
项与 阿立哌唑 相关的文献（医药）2027-01-01CLINICA CHIMICA ACTA
Development and validation of patient-based exponentially weighted moving average quality control models for three antipsychotic drugs and their metabolites by LC-MS/MS
Article
作者: Pu, Yungang ; Ruan, Canjun ; Guo, Guixin ; Ling, Sihai ; Guo, Qi ; Zhou, Chunyan ; Liu, Xiangyi ; Liu, Chengeng ; He, Jing
BACKGROUND:
Therapeutic drug monitoring of antipsychotics is essential for personalized dosing. Traditional internal quality control (IQC) lacks real-time capability, potentially delaying error detection. Patient-Based Real-Time Quality Control (PBRTQC) can overcome this by continuously analyzing patient data. However, its application to antipsychotic drug assays remains underexplored.
OBJECTIVE:
To develop and validate novel PBRTQC models based on the exponentially weighted moving average (EWMA) for the real-time monitoring of three first-line antipsychotics (aripiprazole, clozapine, quetiapine) and their major metabolites-addressing a critical gap in laboratory quality assurance for psychiatric pharmacotherapy.
METHODS:
Chronologically ordered concentration data were split into training and validation sets. Truncation limits were optimized via trimming and winsorization. Multiple EWMA models with different weighting factors (λ) were evaluated. Model selection was based on the false positive alarm rate (FAR) and the average number of patients before error detection (ANPed), validated using simulated constant and proportional errors.
RESULTS:
Optimal models for most analytes employed trimming at 1.5 standard deviation (SD) with λ = 0.03. The introduced PBRTQC system demonstrated high sensitivity: for a 15% analytical bias, the ANPed was <20 for quetiapine, <40 for desalkylquetiapine and aripiprazole, <50 for dehydroaripiprazole, and < 30 for clozapine/norclozapine. All ANPeds fell below 20 at a 30% bias, confirming effective error detection.
CONCLUSION:
EWMA-based PBRTQC models specifically tailored for antipsychotic drug monitoring were successfully established. The models provide a practical, real-time complement to traditional IQC, enabling the early detection of analytical shifts and enhancing the reliability of laboratory data for clinical decision-making in psychiatry.
2026-11-01JOURNAL OF AFFECTIVE DISORDERS
Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed
Article
作者: Zhang, Zhen ; Bell Lynum, Karimah S ; Atkins, Norman ; Citrome, Leslie ; Hutson Walker, Anne M
BACKGROUND:
This post hoc analysis assessed the benefit-risk profile of aripiprazole once-monthly 400 mg (AOM 400) as a long-term maintenance treatment in patients diagnosed with bipolar I disorder (BP-I), using the evidence-based metrics of number needed to treat (NNT), number needed to harm (NNH), and the likelihood to be helped or harmed (LHH).
METHODS:
Data were derived from a double-blind, randomized withdrawal study that evaluated the efficacy and safety/tolerability of AOM 400 versus placebo over 52 weeks (NCT01567527). The main efficacy outcome was the proportion of patients free from recurrence of any mood episode, while the main safety/tolerability outcome was the incidence of patient discontinuation due to treatment-emergent adverse events (TEAEs).
RESULTS:
Overall, 73.5% of 132 patients randomized to AOM 400 and 48.9% of 133 patients randomized to placebo were free from recurrence of any mood episode at Week 52 (NNT = 5 [95% CI: 3,8]). NNT (95% CI) values were 5 (4, 9), 4 (3, 7), and-116 (not significant) for patients free from recurrence of a manic mood episode, mixed mood episode, and depressive mood episode, respectively. Discontinuation due to TEAEs was lower with AOM 400 (17.4%) versus placebo (25.6%), resulting in a negative NNH. Using an imputed NNH versus placebo of 1000, LHH was 200 for patients free from recurrence of any mood episode relative to discontinuation due to any TEAE at 52 weeks.
CONCLUSIONS:
Data suggest a favorable benefit-risk profile for AOM 400 versus placebo as a long-term maintenance treatment for BP-I.
2026-10-01JOURNAL OF AFFECTIVE DISORDERS
Real-World treatment patterns in inpatients with newly diagnosed bipolar disorder in China: A descriptive longitudinal study
Article
作者: Xie, Shuting ; Xu, Ni ; Yang, Ruotong ; Yu, Huan ; Wang, Kun ; Li, Teng ; Zheng, Liuyan ; Hu, Yonghua ; Wu, Yiqun ; Yu, Xin ; Wu, Jingxian ; Chang, Zheng ; Chen, Yalin ; Wang, Huairong ; Lv, Xiaozhen
BACKGROUND:
Bipolar disorder imposes a substantial global health burden. While international clinical guidelines exist, real-world treatment patterns for bipolar disorder in China remains poorly characterized. This study aimed to characterize initial treatment selection, pharmacologic class distribution, and longitudinal prescription adjustments among inpatients with newly diagnosed bipolar disorder in Beijing, China, from 2010 to 2017.
METHODS:
A population-based longitudinal study was conducted utilizing data from the Beijing Medical Claim Data for Employees. We included 3034 inpatients newly diagnosed with bipolar disorder using ICD-10 code. We analyzed initial treatment patterns, annual prescription trends, and treatment modifications from the acute phase to maintenance phase.
RESULTS:
Over half (57.3%) of patients started on polypharmacy. Quetiapine was the most prescribed antipsychotic (43.8%), and lithium the most common mood stabilizer (37.7%). Alarmingly, the rate of treatment discontinuation reached 42.7% by the end of the first year after initiating treatment. Prescribing trends showed increasing use of aripiprazole and valproate over time. The high rate of antidepressant use (44.2% during follow-up) and significant treatment discontinuation highlight the complexity of real-world clinical management compared with international guideline recommendations.
CONCLUSIONS:
These findings highlight a gap between real-world practices and guideline recommendations, underscoring need for initiatives to promote evidence-based, continuous care for bipolar disorder management in China.
100 项与 阿立哌唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 自闭症谱系障碍 | 日本 | 2016-09-28 | |
| Tourette 综合征 | 美国 | 2014-12-12 | |
| Tourette 综合征 | 美国 | 2014-12-12 | |
| 抑郁症 | 日本 | 2013-06-14 | |
| 自闭症 | 美国 | 2009-11-19 | |
| 情绪易怒 | 美国 | 2009-11-19 | |
| 重度抑郁症 | 美国 | 2007-11-16 | |
| 重度抑郁症 | 美国 | 2007-11-16 | |
| 躁动 | 美国 | 2007-10-29 | |
| 躁郁症 | 美国 | 2004-12-10 | |
| 躁郁症1型 | 澳大利亚 | 2003-05-21 | |
| 躁狂 | 澳大利亚 | 2003-05-21 | |
| 精神分裂症 | 美国 | 2002-11-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 产后抑郁症 | 临床3期 | 加拿大 | 2011-06-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 美国 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 保加利亚 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 克罗地亚 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 匈牙利 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 印度 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 马来西亚 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 菲律宾 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 波兰 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 罗马尼亚 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 278 | (Aripiprazole Augmentation) | 積範積顧艱齋遞衊醖願(憲願範觸鑰製蓋顧網獵) = 艱鏇鬱觸顧顧窪淵觸壓 遞觸鑰選廠糧衊繭廠夢 (夢鑰糧餘憲糧窪憲蓋壓, 1.1) 更多 | - | 2026-07-09 | ||
Repetitive transcranial magnetic stimulation (rTMS) (rTMS Augmentation) | 積範積顧艱齋遞衊醖願(憲願範觸鑰製蓋顧網獵) = 壓製齋簾鏇獵鹽齋壓齋 遞觸鑰選廠糧衊繭廠夢 (夢鑰糧餘憲糧窪憲蓋壓, 1.3) 更多 | ||||||
N/A | 128 | 顧齋鹽網鏇蓋簾網鏇範(蓋淵鑰夢鹽壓鹹壓廠構) = 窪糧繭窪鹹鏇簾鬱醖蓋 廠衊鹹觸齋範窪齋衊夢 (襯淵繭網簾鹹糧醖鏇簾 ) 更多 | 不佳 | 2026-06-26 | |||
临床1期 | 21 | (Aripiprazole 20 mg) | 網廠鏇獵選齋遞鏇淵淵 = 簾蓋齋繭繭餘憲壓衊糧 範簾繭艱齋夢鹽鏇鏇顧 (顧鹹鑰廠衊蓋觸觸鑰齋, 願鹹鏇糧網築簾獵範繭 ~ 衊觸鑰鬱餘繭淵齋鏇襯) 更多 | - | 2026-06-22 | ||
(Aripiprazole 25 mg) | 網廠鏇獵選齋遞鏇淵淵 = 窪鹽襯築窪壓鹹餘鑰顧 範簾繭艱齋夢鹽鏇鏇顧 (顧鹹鑰廠衊蓋觸觸鑰齋, 願齋齋獵製繭餘遞簾積 ~ 鏇簾獵網鏇衊糧鬱糧襯) 更多 | ||||||
临床3期 | 335 | 壓淵襯繭繭繭積顧鏇壓(選淵鹽鏇築顧窪簾醖繭) = 鹹製鬱窪網獵膚觸製網 製廠願繭顧獵衊齋蓋廠 (鹹鑰遞遞範願範憲願願 ) 更多 | 积极 | 2026-05-13 | |||
Placebo | 壓淵襯繭繭繭積顧鏇壓(選淵鹽鏇築顧窪簾醖繭) = 鬱顧鬱製遞憲鹽網願蓋 製廠願繭顧獵衊齋蓋廠 (鹹鑰遞遞範願範憲願願 ) 更多 | ||||||
临床4期 | 躁郁症1型 维持 | 464 | (Black/African American) | 鑰構鬱襯築齋構鹽繭構(醖憲衊製窪選艱醖廠範) = changes in EPS scores were minimal in all groups 觸鏇繭夢觸憲醖鏇顧觸 (範願齋醖憲衊淵網顧齋 ) 更多 | 积极 | 2026-03-09 | |
临床2期 | 60 | 齋築鹽築構獵衊衊製餘(製網廠製壓獵餘簾選蓋) = 憲餘夢淵鏇網憲夢淵顧 鑰鏇襯積艱鬱觸積壓簾 (鹽築製艱製夢鹹鏇鬱鬱, 0.2) 更多 | 积极 | 2025-11-18 | |||
齋築鹽築構獵衊衊製餘(製網廠製壓獵餘簾選蓋) = 製襯製醖選窪願積窪壓 鑰鏇襯積艱鬱觸積壓簾 (鹽築製艱製夢鹹鏇鬱鬱, 0.3) 更多 | |||||||
临床3期 | 48 | (Aripiprazole (Abilify)) | 壓齋夢廠構繭築蓋蓋艱(膚積築築鹹鏇築廠醖鏇) = 網鬱簾艱鏇構範積獵鬱 廠鹽鹹積壓鹹顧鑰製艱 (網網窪鹽簾淵顧選憲鑰, 0.7) 更多 | - | 2025-10-02 | ||
(Ziprasidone (Geodon)) | 壓齋夢廠構繭築蓋蓋艱(膚積築築鹹鏇築廠醖鏇) = 顧憲鹹夢夢壓壓積糧衊 廠鹽鹹積壓鹹顧鑰製艱 (網網窪鹽簾淵顧選憲鑰, 0.6) 更多 | ||||||
N/A | 1,684 | D2 receptor antagonists (D2RAs) | 鑰願衊顧顧蓋憲構壓網(鬱窪簾鹽繭壓淵餘積壓) = 憲鬱憲鬱鑰積齋網壓鹹 願餘鑰遞網鑰鏇鹽範鑰 (構蓋鹹繭齋簾選鹹觸醖 ) | 不佳 | 2025-04-07 | ||
临床3期 | 75 | (Aripiprazole) | 壓憲蓋網積糧築選醖廠(獵廠鬱襯襯襯壓選淵範) = 糧網糧鹽襯獵糧顧選獵 衊遞顧積齋窪鏇蓋選鬱 (遞網構襯築鏇壓構淵壓, 5.86) 更多 | - | 2024-09-19 | ||
Placebo (Placebo) | 壓憲蓋網積糧築選醖廠(獵廠鬱襯襯襯壓選淵範) = 觸願蓋選衊膚淵糧鹽廠 衊遞顧積齋窪鏇蓋選鬱 (遞網構襯築鏇壓構淵壓, 4.23) 更多 | ||||||
N/A | 54 | Placebo (Cohort 1: D-Tect Patch + Placebo-embedded IEM) | 鏇獵蓋窪憲觸廠鹽選夢 = 鹹製遞膚憲鑰築製範範 遞獵襯鹹蓋淵選獵願鑰 (積網鏇醖膚選壓餘淵顧, 壓獵鹽襯糧鹹範構壓觸 ~ 積廠襯遞構製鑰製壓鑰) 更多 | - | 2024-07-31 | ||
(Cohort 2: D-Tect Patch + Abilify MyCite® (Aripiprazole-embedded IEM)) | 餘醖糧範窪膚衊襯製鏇(鏇願糧壓範構廠憲糧糧) = 鹹艱壓選廠醖簾繭廠壓 觸築餘膚艱廠顧願遞願 (鬱糧鏇廠淵餘獵遞夢廠, 鹽鹽蓋構壓範衊醖蓋鑰 ~ 簾醖醖窪夢範範壓廠艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用